Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.

Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, Chung RT.

Liver Int. 2009 May;29(5):748-53. doi: 10.1111/j.1478-3231.2009.01973.x. Epub 2009 Feb 9.

2.

Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation.

Rimola A, Londoño MC, Guevara G, Bruguera M, Navasa M, Forns X, García-Retortillo M, García-Valdecasas JC, Rodes J.

Transplantation. 2004 Sep 15;78(5):686-91.

PMID:
15371669
3.

Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.

Guillaud O, Gurram KC, Puglia M, Lilly L, Adeyi O, Renner EL, Selzner N.

Transplant Proc. 2013 Jul-Aug;45(6):2331-6. doi: 10.1016/j.transproceed.2013.01.067.

PMID:
23953545
4.

Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.

Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai R, McCullough AJ, Dasarathy S.

Liver Int. 2015 Mar;35(3):979-85. doi: 10.1111/liv.12611. Epub 2014 Jul 5.

PMID:
24905085
5.

Antifibrotic effect of angiotensin blockers in hypertensive hepatitis C patients.

Bahde R, Kapoor S.

Liver Int. 2009 Nov;29(10):1597; author reply 1598. doi: 10.1111/j.1478-3231.2009.02115.x. Epub 2009 Sep 9. No abstract available.

PMID:
19744164
6.

The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.

Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT.

Dig Dis Sci. 2011 Feb;56(2):564-8. doi: 10.1007/s10620-010-1507-8. Epub 2010 Dec 7.

7.

Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation.

Cholongitas E, Vibhakorn S, Lodato F, Burroughs AK.

Liver Int. 2010 Feb;30(2):334-5. doi: 10.1111/j.1478-3231.2009.02059.x. Epub 2009 Jun 9. No abstract available.

PMID:
19515217
8.

Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.

Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH.

Am J Hypertens. 1999 May;12(5):451-9.

PMID:
10342782
9.

Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis.

Imakiire T, Kikuchi Y, Yamada M, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S.

Hypertens Res. 2007 Jul;30(7):635-42.

PMID:
17785932
10.

Essential hypertension and chronic viral hepatitis.

Parrilli G, Manguso F, Orsini L, Coccoli P, Vecchione R, Terracciano L, De Luca N, Cirillo N, Abazia C, Budillon G, Marchesini G.

Dig Liver Dis. 2007 May;39(5):466-72. Epub 2007 Mar 21.

PMID:
17369113
11.

Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats.

Karimian G, Mohammadi-Karakani A, Sotoudeh M, Ghazi-Khansari M, Ghobadi G, Shakiba B.

Biomed Pharmacother. 2008 Jun;62(5):312-6. doi: 10.1016/j.biopha.2007.10.020. Epub 2007 Dec 3.

PMID:
18191530
12.

Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.

Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL.

Hypertension. 2006 Aug;48(2):271-7. Epub 2006 Jun 19.

13.

Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.

Krairittichai U, Chaisuvannarat V.

J Med Assoc Thai. 2009 May;92(5):611-7.

PMID:
19459520
14.

Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.

Erdem Y, Usalan C, Haznedaroğlu IC, Altun B, Arici M, Yasavul U, Turgan C, Cağlar S.

Am J Hypertens. 1999 Nov;12(11 Pt 1):1071-6.

PMID:
10604482
15.

Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.

Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet C, Ménard J.

J Hypertens. 2000 Aug;18(8):1139-47.

PMID:
10954007
16.
17.

Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study.

Ueki M, Koda M, Shimizu T, Mitsuta A, Yamamoto T, Murawaki Y.

Hepatogastroenterology. 2009 Jul-Aug;56(93):1100-4.

PMID:
19760950
20.

Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.

Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP.

J Hypertens. 2005 Nov;23(11):2093-100.

PMID:
16208153

Supplemental Content

Support Center